Melbourne, April 28, 2026, 06:08 AEST
CSL Limited’s on-market buyback has now topped 6 million shares, keeping capital return plans in the spotlight as investors gauge whether the Australian biotech’s stock has finally stabilized. According to an ASX filing dated Monday, the company picked up another 86,383 shares during the prior session, spending A$11.2 million. That brings the ongoing tally to 6,084,879 shares repurchased, with roughly A$1.024 billion spent so far. CSL’s buyback program allows for up to US$750 million of ordinary shares.
Timing counts here. CSL finished Monday at A$131.82, gaining 1.4%, yet still hovering only slightly above Friday’s 52-week low of A$127.75. The stock traded between A$129.61 and A$132.21 during the session, according to price data.
Pressure followed the Pentagon’s announcement that U.S. troops are off the hook for flu shots. Defense Secretary Pete Hegseth confirmed the mandate’s end. Vaccine producers—Sanofi, CSL Seqirus, GSK, and AstraZeneca—were contacted for comment by Reuters in light of the shift.
For CSL, the policy change hit right where things were already looking soft. Reuters noted the U.S. remains CSL’s biggest revenue driver, with Seqirus—its vaccines arm—posting around $2.17 billion in revenue for fiscal 2025. Marc Jocum of GlobalXETFs called the Pentagon’s decision “the worst possible time” for extra pressure, and Hebe Chen at Vantage Markets flagged both fading earnings momentum and a strategy confidence gap. Reuters
The half-year numbers lay it out: the market’s tough stance comes down to results like these. CSL’s total revenue for the six months ended Dec. 31 came in at US$8.3 billion, off 4% in constant currency. Underlying NPATA dropped 7% to US$1.9 billion. Bottom line, reported net profit slumped 81% to just US$401 million. Chief Financial Officer Ken Lim summed it up — CSL was “not satisfied” with performance.
Seqirus didn’t quite make up the difference. The company reported the unit brought in US$1.6 billion for the first half, a 2% drop. Global seasonal influenza sales ticked up 1%, this despite a dip in U.S. immunisation rates. FLUAD managed a 6% gain, while FLUCELVAX edged down 1%.
The buyback comes as CSL reshuffles its top ranks. Gordon Naylor took over as interim CEO and managing director from Feb. 11, stepping in after Paul McKenzie’s retirement. Naylor’s no stranger to CSL—he’s the former CFO and ex-president of Seqirus. Chair Brian McNamee gave him “full authority” for the duration of the interim stretch.
U.S. policy risk remains in play. On April 7, CSL informed the ASX that it believed the majority of its U.S. product sales would likely avoid the proposed pharmaceutical tariffs outlined in Section 232 of the Trade Expansion Act. The company pointed out that Fluad, its key Seqirus product for the U.S., is produced in the United Kingdom—where the tariff stood at 10%, set to drop to zero. Any tariff effect would not kick in until Sept. 29, 2026.
The risk here is straightforward: buybacks could take some heat out of trading, but they don’t guarantee more buyers. If U.S. service members don’t opt for voluntary flu shots in numbers that make up for the loss of forced vaccinations, and if the wider U.S. public keeps shunning vaccines, Seqirus faces the same vulnerability. CSL, for its part, still has to deliver on plasma, Vifor, and those promised cost cuts.
Don’t expect a decisive move in just one day’s filing. Investors are watching if CSL steps up purchases with the stock hovering near multi-year lows, eyeing any rebound in U.S. flu orders. Naylor’s challenge: prove the transformation program delivers earnings instead of yet another reset.
